×
返回 Agenda
Welcoming Remarks and Session 1: Keynote Address - The Coming of Age of Oligonucleotide-Based Therapeutics
Session Chair(s)
Ronald Wange, PhD
Associate Director for Pharm/Tox OND
FDA, United States
Scott Henry, PhD
Senior Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc., United States
In her keynote address, Dr. Woodcock will provide her perspective on the current state of RNA-directed therapeutics, the challenges that still confront the field, and a clear-eyed view of the latent potential that these drugs have to treat a broad array of diseases that currently lack effective treatment options.
Speaker(s)
Speaker
Janet Woodcock, MD
United States
Retired, Principal Deputy Commissioner, FDA